NCT00754312View on ClinicalTrials.gov

A Phase I, Multicenter, Open Label Study on the Effects of SNDX-275 on Expression of Biomarkers in Subjects With Newly Diagnosed Breast Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Breast Cancer
Interventions
DRUG

SNDX-275

Trial Locations (1)

Unknown

Monet Bowling, MD, Indianapolis

Sponsors
All Listed Sponsors
lead

Syndax Pharmaceuticals

INDUSTRY